What Is IGF-1 LR3? Research Overview
IGF-1 LR3 is the long-acting analog of insulin-like growth factor 1, engineered to evade binding proteins and study IGF-1 receptor signaling downstream of growth hormone.
"What is IGF-1 LR3?" — it is the Long R3 analog of insulin-like growth factor 1, a modified growth factor engineered for extended activity in research models. Where the GH secretagogues raise growth hormone, IGF-1 LR3 sits one step downstream: IGF-1 is the mediator that carries much of GH's signal to tissues. This research-use-only overview explains what the molecule is, what its modifications do, and where it fits on the growth-hormone axis.
What is IGF-1 LR3?
Insulin-like growth factor 1 (IGF-1) is a peptide hormone, produced largely in the liver in response to growth hormone, that signals through the IGF-1 receptor to drive cellular growth and proliferation. IGF-1 LR3 ("Long R3 IGF-1") is an 83-amino-acid analog of native IGF-1 with two engineered changes: an arginine substituted for glutamate at position 3 (the "R3"), and a 13-residue extension peptide added to the N-terminus (the "Long"). Together those modifications make it behave very differently from the native hormone in circulation.
Why the LR3 modifications matter
Native IGF-1 is tightly bound in circulation by IGF-binding proteins (IGFBPs), a family of six carrier proteins that regulate how much free, active IGF-1 is available at any moment. The R3 substitution sharply reduces IGF-1 LR3's affinity for those binding proteins, so far more of the analog stays free and able to engage its receptor. The N-terminal extension further increases potency and stability. The combined result studied in the literature is a much longer functional half-life and a higher free-active fraction than native IGF-1 — which is why LR3 is the form typically chosen for research that needs a durable IGF-1 signal.
How IGF-1 LR3 signals
Once free, IGF-1 LR3 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Activation triggers two major intracellular cascades — the PI3K/Akt pathway, associated with cell survival and metabolism, and the MAPK/ERK pathway, associated with proliferation. Because these are the same cascades native IGF-1 engages, IGF-1 LR3 is studied as a tool for sustaining IGF-1R signaling in cell and tissue models without the rapid clearance that limits the native hormone.
IGF-1R is structurally related to the insulin receptor, and the two can form hybrid receptors, so IGF-1 signaling overlaps with insulin signaling at the cellular level. The extended free fraction of IGF-1 LR3 is what lets researchers hold the IGF-1R input steady long enough to read out these cascades cleanly in a culture experiment, rather than chasing the brief, binding-protein-buffered signal that native IGF-1 produces.
Where IGF-1 sits on the GH axis
The classic axis is GH → IGF-1 → tissue effect. Growth hormone, released from the pituitary, stimulates IGF-1 production; IGF-1 then mediates many of the downstream growth signals. That is why IGF-1 LR3 is studied alongside the GH side of the axis — the GH-secretagogue research (CJC-1295 + ipamorelin) and the recombinant hormone HGH 191aa all converge on IGF-1 signaling. Studying IGF-1 LR3 directly lets researchers probe the downstream mediator without depending on upstream GH release.
How IGF-1 LR3 is characterized in research
- Structure: 83-aa analog — native IGF-1 plus an N-terminal 13-residue extension and an Arg-for-Glu swap at position 3
- Receptor: signals through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase
- Downstream cascades: PI3K/Akt and MAPK/ERK
- IGFBP evasion: the R3 substitution lowers binding-protein affinity, raising free-fraction activity
- Kinetics: much longer functional half-life than native IGF-1 in reported models
- Position on the axis: downstream mediator of growth-hormone signaling
IGF-1 LR3 vs recombinant growth hormone
Because IGF-1 mediates much of growth hormone's effect, IGF-1 LR3 and recombinant GH such as HGH 191aa are sometimes studied as alternative entry points to the same downstream biology. The distinction is where each acts on the axis. Recombinant GH works at the top — it drives IGF-1 production and also has direct, IGF-1-independent effects of its own on metabolism. IGF-1 LR3 works at the mediator level, engaging IGF-1R directly and bypassing the question of how much GH the system produces. Researchers choosing between them are really choosing which node of the GH → IGF-1 axis they want to manipulate.
Handling and quality
IGF-1 LR3 is supplied lyophilized and reconstituted with bacteriostatic water before in-vitro use; the reconstitution calculator returns concentration and aliquot volume for any vial size. Every IGF-1 LR3 lot from Eon Research ships lyophilized in multi-vial research kits from our US facility within 48 hours with tracking.
Frequently asked questions
What is IGF-1 LR3?
It is the Long R3 analog of insulin-like growth factor 1 — an 83-amino-acid peptide with an N-terminal extension and an arginine-for-glutamate substitution at position 3 that reduces its binding to IGF-binding proteins, giving it a much longer functional half-life than native IGF-1. It is research-use-only.
How is IGF-1 LR3 different from regular IGF-1?
The LR3 modifications (the N-terminal Long extension and the R3 substitution) lower its affinity for IGF-binding proteins and increase stability, so more of the analog stays free and active for longer in research models than native IGF-1, which is largely bound by IGFBPs in circulation.
How does IGF-1 LR3 relate to growth hormone?
IGF-1 is the downstream mediator of growth hormone: GH from the pituitary stimulates IGF-1 production, and IGF-1 then signals through the IGF-1 receptor via the PI3K/Akt and MAPK/ERK pathways. IGF-1 LR3 is studied as a long-acting analog of that mediator.